Cymat Technologies Ltd. (CVE:CYM) Director Martin Joseph Mazza purchased 40,357 shares of the business’s stock in a transaction on Monday, November 4th. The shares were bought at an average cost of C$0.31 per share, with a total value of C$12,308.89. Following the acquisition, the director now directly owns 40,357 shares of the company’s stock, valued at approximately C$12,308.89.
Martin Joseph Mazza also recently made the following trade(s):
- On Thursday, October 3rd, Martin Joseph Mazza sold 12,000 shares of Cymat Technologies stock. The shares were sold at an average price of C$0.31, for a total value of C$3,720.00.
- On Thursday, August 29th, Martin Joseph Mazza sold 4,000 shares of Cymat Technologies stock. The shares were sold at an average price of C$0.30, for a total value of C$1,200.00.
- On Tuesday, August 27th, Martin Joseph Mazza sold 4,500 shares of Cymat Technologies stock. The shares were sold at an average price of C$0.29, for a total value of C$1,305.00.
CVE:CYM opened at C$0.29 on Thursday. The stock has a 50-day simple moving average of C$0.31 and a two-hundred day simple moving average of C$0.31. Cymat Technologies Ltd. has a 52-week low of C$0.19 and a 52-week high of C$0.43. The firm has a market capitalization of $11.97 million and a PE ratio of -8.29.
Cymat Technologies (CVE:CYM) last released its quarterly earnings data on Friday, September 27th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$0.65 million during the quarter.
Cymat Technologies Company Profile
Cymat Technologies Ltd., a materials technology company, manufactures and sells stabilized aluminum foam products worldwide. The company offers 3-D and low pressure casting products for use in defense and military, automotive, and other applications. It also provides architectural materials under the Alusion brand name; and automotive and blast mitigation products under the SmartMetal brand name.
Featured Story: Hedge Funds Explained
Receive News & Ratings for Cymat Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cymat Technologies and related companies with MarketBeat.com's FREE daily email newsletter.